Modulation of Limbic Circuitry Predicts Treatment Response to Antipsychotic Medication: A Functional Imaging Study in Schizophrenia

被引:0
|
作者
Adrienne C Lahti
Martin A Weiler
Henry H Holcomb
Carol A Tamminga
Karen L Cropsey
机构
[1] University of Alabama at Birmingham,Department of Psychiatry
[2] Maryland Psychiatric Research Center,Department of Psychiatry
[3] University of Maryland School of Medicine,undefined
[4] UT Southwestern Medical Center,undefined
来源
Neuropsychopharmacology | 2009年 / 34卷
关键词
schizophrenia; PET; rCBF; haloperidol; olanzapine;
D O I
暂无
中图分类号
学科分类号
摘要
The regional neuronal changes taking place in the early and late stages of antipsychotic treatment are still not well characterized in humans. In addition, it is not known whether these regional changes are predictive of or are correlated with treatment response. Using PET with 15O, we evaluated the time course of regional cerebral blood flow (rCBF) patterns generated by a first (haloperidol) and a second (olanzapine) generation antipsychotic drug in patients with schizophrenia during a 6-week treatment trial. Patients were initially scanned after withdrawal of all psychotropic medication (2 weeks), and then blindly randomized to treatment with haloperidol (n=12) or olanzapine (n=17) for a period of 6 weeks. Patients were scanned again after 1 and 6 weeks of treatment. All assessments, including scanning sessions, were obtained in a double-blind manner. As hypothesized, we observed rCBF changes that were common to both the drugs, implicating cortico-subcortical and limbic neuronal networks in antipsychotic action. In addition, in these regions, some patterns seen at weeks 1 and 6 were distinctive, indexing neuronal changes related to an early (ventral striatum, hippocampus) and consolidated (anterior cingulate/medial frontal cortex) stage of drug response. Finally, both after 1 and 6 weeks of treatment, we observed differential patterns of rCBF activation between good and poor responders. After 1 week of treatment, greater rCBF increase in the ventral striatum and greater decrease in the hippocampus were associated with good response.
引用
收藏
页码:2675 / 2690
页数:15
相关论文
共 50 条
  • [21] The heterogeneity of antipsychotic response in the treatment of schizophrenia
    Case, M.
    Stauffer, V. L.
    Ascher-Svanum, H.
    Conley, R.
    Kapur, S.
    Kane, J. M.
    Kollack-Walker, S.
    Jacob, J.
    Kinon, B. J.
    PSYCHOLOGICAL MEDICINE, 2011, 41 (06) : 1291 - 1300
  • [22] The Heterogeneity of Antipsychotic Response in the Treatment of Schizophrenia
    Case, Michael G.
    Stauffer, Virginia L.
    Ascher-Svanum, Haya
    Conley, Robert
    Kapur, Shitij
    Kane, John M.
    Kollack-Walker, Sara
    Jacob, Jayanthi
    Kinon, Bruce J.
    BIOLOGICAL PSYCHIATRY, 2010, 67 (09) : 76S - 76S
  • [23] Baseline structural and functional magnetic resonance imaging predicts early treatment response in schizophrenia with radiomics strategy
    Cui, Long-Biao
    Fu, Yu-Fei
    Liu, Lin
    Wu, Xu-Sha
    Xi, Yi-Bin
    Wang, Hua-Ning
    Qin, Wei
    Yin, Hong
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2021, 53 (06) : 1961 - 1975
  • [24] DRD2 promoter region variation predicts sustained response to antipsychotic medication in first episode schizophrenia
    Lencz, T
    Robinson, DG
    Xu, K
    Ekholm, J
    Sevy, S
    Gunduz-Bruce, H
    Woerner, MG
    Kane, JM
    Goldman, D
    Malhotra, AK
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S196 - S197
  • [25] Neuroinflammation in schizophrenia and effects of antipsychotic medication - a PET study
    Holmes, S. E.
    Hinz, R.
    Green, M.
    Anton-Rodriguez, J.
    Gerhard, A.
    Drake, R.
    Talbot, P. S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S135 - S135
  • [26] Neuroinflammation in schizophrenia and effects of antipsychotic medication - a PET study
    Holmes, S. E.
    Hinz, R.
    Green, M.
    Anton-Rodriguez, J. M.
    Gerhard, A.
    Drake, R.
    Talbot, P. S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S69 - S70
  • [27] A comparative study of antipsychotic medication taking in people with schizophrenia
    McCann, Terence V.
    Deans, Cecil
    Clark, Eileen
    Lu, Sai
    INTERNATIONAL JOURNAL OF MENTAL HEALTH NURSING, 2008, 17 (06) : 428 - 438
  • [28] Schizophrenia Polygenic Risk Score Predicts Antipsychotic Treatment Response in Patients With First Episode Psychosis
    Zhang, Jianping
    Robinson, Delbert
    Yu, Jin
    Fleischhacker, Wolfgang
    Kahn, Rene
    Kane, John
    Malhotra, Anil
    Lencz, Todd
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S569 - S570
  • [29] Medication management of antipsychotic treatment in schizophrenia-A narrative review
    Isohanni, Matti
    Jaaskelainen, Erika
    Miller, Brian J.
    Hulkko, Anja
    Tiihonen, Jari
    Moeller, Hans-Jurgen
    Hartikainen, Sirpa
    Huhtaniska, Sanna
    Lieslehto, Johannes
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2021, 36 (02)
  • [30] THE TREATMENT OF SCHIZOPHRENIA WITH THE ADDITION OF ATYPICAL ANTIPSYCHOTIC MEDICATION TO TRAVEL THERAPY
    Liu, Deng
    SCHIZOPHRENIA BULLETIN, 2025, 51 : S3 - S3